Jinhai Medical Technology Past Earnings Performance
Past criteria checks 0/6
Jinhai Medical Technology's earnings have been declining at an average annual rate of -58.7%, while the Professional Services industry saw earnings growing at 2.6% annually. Revenues have been declining at an average rate of 2.9% per year.
Key information
-58.7%
Earnings growth rate
-58.0%
EPS growth rate
| Professional Services Industry Growth | 23.9% |
| Revenue growth rate | -2.9% |
| Return on equity | -28.3% |
| Net Margin | -17.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Jinhai Medical Technology Limited's (HKG:2225) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Dec 16
Jinhai Medical Technology (HKG:2225) Has Debt But No Earnings; Should You Worry?
Nov 05Why We're Not Concerned About Jinhai Medical Technology Limited's (HKG:2225) Share Price
Oct 06The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon
Jun 19Investors Appear Satisfied With Jinhai Medical Technology Limited's (HKG:2225) Prospects As Shares Rocket 26%
May 13Subdued Growth No Barrier To Jinhai Medical Technology Limited (HKG:2225) With Shares Advancing 31%
Mar 17What Jinhai International Group Holdings Limited's (HKG:2225) 50% Share Price Gain Is Not Telling You
Jan 31Here's What's Concerning About Jinhai International Group Holdings' (HKG:2225) Returns On Capital
Jun 06Be Wary Of Jinhai International Group Holdings (HKG:2225) And Its Returns On Capital
Mar 07Revenue & Expenses Breakdown
How Jinhai Medical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 60 | -10 | 26 | 0 |
| 31 Mar 24 | 53 | -7 | 21 | 0 |
| 31 Dec 23 | 46 | -3 | 17 | 0 |
| 30 Sep 23 | 33 | -2 | 14 | 0 |
| 30 Jun 23 | 20 | 0 | 11 | 0 |
| 31 Mar 23 | 21 | 0 | 10 | 0 |
| 31 Dec 22 | 22 | 0 | 10 | 0 |
| 30 Sep 22 | 25 | 0 | 10 | 0 |
| 30 Jun 22 | 27 | 0 | 9 | 0 |
| 31 Mar 22 | 24 | 0 | 9 | 0 |
| 31 Dec 21 | 22 | 0 | 9 | 0 |
| 30 Sep 21 | 20 | 0 | 9 | 0 |
| 30 Jun 21 | 18 | 1 | 9 | 0 |
| 31 Mar 21 | 20 | 1 | 10 | 0 |
| 31 Dec 20 | 22 | 1 | 11 | 0 |
| 30 Sep 20 | 31 | 1 | 12 | 0 |
| 30 Jun 20 | 40 | 0 | 12 | 0 |
| 31 Mar 20 | 46 | 0 | 13 | 0 |
| 31 Dec 19 | 52 | -1 | 13 | 0 |
| 30 Sep 19 | 51 | -1 | 13 | 0 |
| 30 Jun 19 | 51 | -2 | 13 | 0 |
| 31 Mar 19 | 49 | -3 | 13 | 0 |
| 31 Dec 18 | 47 | -4 | 13 | 0 |
| 30 Sep 18 | 46 | -2 | 11 | 0 |
| 30 Jun 18 | 44 | -1 | 9 | 0 |
| 31 Mar 18 | 44 | 1 | 8 | 0 |
| 31 Dec 17 | 44 | 2 | 7 | 0 |
| 31 Dec 16 | 45 | 7 | 8 | 0 |
| 31 Dec 15 | 46 | 6 | 8 | 0 |
| 31 Dec 14 | 45 | 4 | 9 | 0 |
Quality Earnings: 2225 is currently unprofitable.
Growing Profit Margin: 2225 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2225 is unprofitable, and losses have increased over the past 5 years at a rate of 58.7% per year.
Accelerating Growth: Unable to compare 2225's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2225 is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (33.8%).
Return on Equity
High ROE: 2225 has a negative Return on Equity (-28.25%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jinhai Medical Technology Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|